Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors Meeting Abstract
| Authors: | Bendell, J. C.; Bedard, P.; Bang, Y. J.; LoRusso, P.; Hodi, S.; Gordon, M.; D'Angelo, S.; Desai, J.; Garralda, E.; Italiano, A.; Ahn, M. J.; Cervantes, A.; Wainberg, Z.; Calvo, E.; Gil-Martin, M.; Martinez-Garcia, M.; Bahleda, R.; Cassier, P.; Delord, J. P.; Prawira, A.; Melero, I.; Emens, L.; Romano, E.; Miller, K.; Hsieh, R. W.; Xue, C.; Morrissey, K.; Twomey, P.; Gash, K.; Patil, N. S.; Grogan, J.; Meng, R.; Cho, B.; Kim, T. W. |
| Abstract Title: | Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors |
| Meeting Title: | 111th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 80 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2020 Apr 27-28/Jun 22-24 |
| Meeting Location: | Philadelphia, PA |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2020-08-01 |
| Language: | English |
| ACCESSION: | WOS:000590059302193 |
| DOI: | 10.1158/1538-7445.Am2020-ct302 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: CT302 -- Due to COVID-19 pandemic, the conference was held virtually -- Source: Wos |
